Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Fresenius Kabi expanded its footprints with the acceptance of MAA and BLA of its MSB11455 (biosimilar, pegfilgrastim) in the EU and the US respectively, and also signed an agreement with Medec to commercialize Idacio (adalimumab, biosimilar) in…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it
The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019
PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
The global biopharma companies are developing novel therapies & devices which is- in turn- enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position
The top 20 companies chartbusters changed their 2019 ranking- but the history of Johnson and Johnson did not change and it continued being at the…
The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020.
Date…
The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 31 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entity and 17 Biologics while breaking its past year's records of approval. However, there is a significant…
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…
The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology- Hematology and multiple diseases but due to a drastic increase in the immune disorders- Immunology segment has been widely spared across the globe. In the top 20…
The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced- effective- and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top…
The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major revenue generator in 2018- with the development of new products and devices. The year 2018 also proved to be a record with approval of 55…

